MSGS trades 25.6% below Wall Street's consensus target of $496.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MSGS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 29 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Madison Square Garden Sports Corp. (MSGS) has a Wall Street consensus price target of $496.00, based on estimates from 29 covering analysts. With the stock currently trading at $394.80, this represents a potential upside of +25.6%. The company has a market capitalization of $9.50B.
Analyst price targets range from a low of $450.00 to a high of $584.00, representing a 27% spread in expectations. The median target of $475.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 20 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, MSGS trades at a trailing P/E of 1233.8x. Analysts expect EPS to grow -171.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $11.23, with bear and bull scenarios of $7.07 and $14.79 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MANUManchester United plc | $3.5B | $20.49 | $17.95 | -12.4% | Hold | — | 10 |
 FWONKLiberty Media Corporation | $23.4B | $93.25 | $118.83 | +27.4% | Buy | 51.6x | 25 |
 BRLSBorealis Foods Inc. | $29M | $1.34 | — | — | — | — | — |
 WBDWarner Bros. Discovery, Inc. | $77.1B | $30.76 | $31.00 | +0.8% | Hold | — | 32 |
 MSGEMadison Square Garden Entertainment Corp. | $3.7B | $78.49 | $92.33 | +17.6% | Hold | 68.2x | 13 |
 EPREPR Properties | $4.4B | $56.92 | $65.50 | +15.1% | Hold | 18.6x | 22 |
 CHDNChurchill Downs Incorporated | $5.6B | $80.46 | $132.00 | +64.1% | Buy | 11.6x | 23 |
 DKNGDraftKings Inc. | $10.5B | $21.25 | $33.56 | +57.9% | Buy | 181.2x | 48 |
 PENNPENN Entertainment, Inc. | $2.1B | $15.56 | $24.60 | +58.1% | Buy | 18.2x | 47 |
 NFLXNetflix, Inc. | $297.1B | $71.36 | $91.56 | +28.3% | Buy | 19.8x | 99 |
Quick answers to the most common questions about buying MSGS stock.
The consensus Wall Street price target for MSGS is $496, representing 25.6% upside from the current price of $394.8. With 29 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MSGS has a consensus rating of "Buy" based on 29 Wall Street analysts. The rating breakdown is predominantly bullish, with 20 Buy/Strong Buy ratings. The consensus 12-month price target of $496 implies 25.6% upside from current levels.
MSGS's current price is $394.8 with a consensus target of $496 (25.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $584 for MSGS, while the most conservative target is $450. The consensus of $496 represents the median expectation. Our quantitative valuation model projects a bull case target of $15 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
MSGS is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 20 have Buy ratings, 9 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MSGS stock forecast based on 29 Wall Street analysts shows a consensus price target of $496, with estimates ranging from $450 (bear case) to $584 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $11, with bear/bull scenarios of $7/$15.
Our quantitative valuation model calculates MSGS's fair value at $11 (base case), with a bear case of $7 and bull case of $15. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
Wall Street analysts are very optimistic on MSGS, with a "Buy" consensus rating and $496 price target (25.6% upside). 20 of 29 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MSGS analyst price targets range from $450 to $584, a 27% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $496 consensus represents the middle ground. Our model's $7-$15 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.